QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Pregnancy and Breastfeeding Pharmacovigilance

Test your understanding of the concepts covered by GVP Product- or Population-Specific Considerations III: Pregnancy and Breastfeeding.

Question 1 of 10Pass mark: 80%

Question 1 of 10 When is pre-conception exposure especially relevant to pregnancy pharmacovigilance?

Only when the medicine is administered intravenously When the product has a long half-life, persistent biological effects or a plausible effect on reproductive outcomes Only when conception occurs on the day of the last dose Never, because exposure before conception cannot affect later outcomes

Question 2 of 10 Which communication best supports informed treatment decisions when pregnancy safety evidence is limited?

State that the medicine is safe because no definitive risk has been proven State that the medicine is harmful because evidence is incomplete Explain what is known, what remains uncertain, the risks of untreated disease and any available management options Provide only a list of possible fetal effects to ensure maximum caution

Question 3 of 10 Why is gestational timing particularly important when evaluating a suspected pregnancy-related safety signal?

Timing determines whether the report is legally valid Different developmental stages and exposure periods are associated with different potential outcomes Timing is needed only for calculating maternal adherence Timing eliminates the need to consider background risk

Question 4 of 10 Why can the same breast-milk exposure have different clinical implications for different infants?

Infant susceptibility is unrelated to development Prematurity, body weight, organ maturation and renal or hepatic function can influence handling and effects Older infants always have greater toxicity Only the mother’s dose determines infant risk

Question 5 of 10 Which comparator is generally most appropriate in a pregnancy epidemiology study?

Whichever comparator produces the largest apparent difference A comparator selected to reflect the causal question, such as a disease-matched or otherwise appropriate reference group No comparator, because background rates are not relevant Only healthy non-pregnant adults

Question 6 of 10 When might adjusting the interval between maternal dosing and breastfeeding be a reasonable risk-management consideration?

Whenever a medicine is detectable in milk, regardless of pharmacology When the product’s pharmacokinetic profile indicates that timing could meaningfully reduce infant exposure and the strategy is practical and safe Only when the infant has already experienced a serious adverse reaction Whenever the mother requests it, without assessing treatment effectiveness

Question 7 of 10 A pregnancy or breastfeeding concern becomes sufficiently important to require structured monitoring. Which RMP interpretation is most appropriate?

The concern should be ignored until causality is proven Pregnancy exposure automatically requires a restriction in the product information The RMP should reflect the concern or missing information, with additional activities considered according to the evidence gap and regulatory assessment The issue should be managed only through individual case processing

Question 8 of 10 A product is detectable in breast milk, but the infant has no reported symptoms. Which interpretation is best?

Detection proves clinically important infant toxicity Detection proves that breastfeeding must stop The finding establishes presence in milk but not necessarily meaningful infant exposure or harm The finding proves that the infant received the maternal dose

Question 9 of 10 Which information is most useful for estimating an infant’s exposure through breast milk?

The maternal dose alone Milk concentration, estimated milk intake, dosing and feeding timing, and relevant infant characteristics The adult therapeutic range alone The duration of the mother’s illness without treatment details

Question 10 of 10 Why may qualitative clinical review complement automated signal detection for pregnancy outcomes?

Automated methods cannot be used for any pregnancy-related data Small exposure numbers and heterogeneous outcomes can limit the informativeness of routine statistical methods Clinical review removes the need for epidemiological analysis Qualitative review automatically establishes causality

Knowledge Assessment: Pregnancy and Breastfeeding Pharmacovigilance

Cookie Settings